Barr’s Duramed President Ben-Maimon Plans Departure
This article was originally published in The Tan Sheet
Executive Summary
Barr will start searching for a successor for Carole Ben-Maimon, MD, President and COO of its Duramed Research subsidiary, as soon as possible, the firm announced Dec. 19
|
Barr will start searching for a successor for Carole Ben-Maimon, MD, President and COO of its Duramed Research subsidiary, as soon as possible, the firm announced Dec. 19. The exec plans to resign from the company in September 2006 to pursue "new opportunities," according to Barr. Ben-Maimon will continue to manage the firm's proprietary product research organization until a replacement is chosen. She will also remain a member of the company's Board of Directors until the end of her one-year term in November 2006, Barr stated. CEO Bruce Downey commended Ben-Maimon's "many contributions to the company as a whole, and in particular her achievements in building our proprietary products research organization into an innovator of women's healthcare pharmaceutical products." "We are grateful that Carole has agreed to remain as a member of the management team until we can identify a successor so that the momentum of our research activities will continue to accelerate," Downey said. Ben-Maimon's replacement will assume leadership over Barr's four NDAs currently pending at FDA, including the Plan B Rx-to-OTC switch application. The exec presented the case for OTC status for the emergency contraceptive at a 2003 meeting of the Nonprescription Drugs and Reproductive Health Drugs advisory panels ( (Also see "FDA Panels Debate Pricing, Promotions For Plan B OTC" - Pink Sheet, 22 Dec, 2003.), p. 4). "At this juncture in my career, I am now looking to take my skills into new arenas," Ben-Maimon said. "We have built a very talented organization, focused our proprietary research activities, and established a pipeline of products that offer the potential...to drive Barr's proprietary products business forward." Ben-Maimon has been instrumental in developing and leading Barr's proprietary development team since joining the firm in 2001. Her resume includes the launch of the Seasonale oral contraceptive, extending Duramed's line of synthetic estrogen products and developing products based on Barr's vaginal ring drug delivery technology. - Melina Vissat |